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Introduction {#sec1}
============

Spermatogonial stem cells (SSCs) undergo continuous self-renewal and differentiation, which underlies the lifelong maintenance of male fertility ([@bib9], [@bib28]). Although embryonic stem cells have been used for germline modification for decades, SSCs represent an alternative resource for producing genetically modified animals because SSCs are the only stem cells in the germline ([@bib24], [@bib19]). However, because SSCs comprise only a small population in testes (0.02%--0.03% of total germ cells) and are surrounded by somatic cells ([@bib28], [@bib46]), gene transduction into SSCs has met with limited success. Nevertheless, development of spermatogonial transplantation techniques has provided the first opportunity for SSC manipulation and transfection. SSCs microinjected into the seminiferous tubules of infertile animals reinitiated spermatogenesis and resulted in fertile sperm ([@bib3]). By transfecting SSCs before transplantation, transgenic offspring were born ([@bib35]). *In vitro* SSC culture techniques further improved transfection efficiency and provided an opportunity for genetic selection of transfected clones. Adding fibroblast growth factor 2 and glial cell line-derived neurotrophic factor (GDNF), both of which are SSC self-renewal factors, to testis cultures allowed for long-term *in vitro* expansion of SSCs, which can proliferate for more than 2 years without losing fertility ([@bib15]). These cells, which were designated as germline stem (GS) cells, allow production of transgenic or knockout (KO) animals after transplantation of drug-selected GS cell clones into seminiferous tubules ([@bib16], [@bib17]). More recent experiments also demonstrated successful gene editing using similar approaches ([@bib6], [@bib40], [@bib52]). Development of transplantation and culture techniques has greatly improved the utility of SSCs for germline modification.

Despite these successes, there is still a considerable room to improve SSC manipulation techniques. Low gene transduction efficiency has been a major problem in SSC research. Although most of the conventional transfection techniques can be applied to SSCs, difficulties in drug selection and the slow growth of GS cells have hampered efficient clonal selection. Among several transfection methods, SSCs have been most successfully transfected by virus vectors. Retroviruses (RVs) were the first vectors used to transduce SSCs ([@bib34]). However, because RVs have very low transduction efficiency, lentiviruses (LVs) are more widely used for SSC transduction. Unlike conventional RVs, LVs can transduce non-dividing cells, which makes them useful for transducing tissue stem cells that rarely divide or do not divide at all. Although RVs and LVs integrate into the host genome, adenoviruses (AVs) do not integrate into the genome. Moreover, because AVs can be concentrated at higher titers, AVs transduce SSCs more efficiently than do LVs ([@bib44]). However, the major problem with AVs is their toxicity, because continued exposure to AVs induces apoptosis of GS cells. Fortunately, this problem of cell toxicity has recently been overcome by adeno-associated viruses (AAVs) ([@bib48], [@bib49]). AAVs have much less toxicity and transduce SSCs without integrating into the host genome. However, application of AAVs is often limited by their relatively small insert size (\~4.5 kb).

Although these virus vectors have been used in many SSC studies, we and others recently tested the potential of Sendai virus (SV) for SSC transduction ([@bib42], [@bib50]). SV is a non-segmented negative-strand RNA virus of the *Paramyxoviridae* family ([@bib25], [@bib26], [@bib51]). SV was discovered in Japan in 1952 when an outbreak of newborn pneumonitis occurred at Tohoku University. SVs was found not to be responsible for the pneumonitis or to be pathogenic to humans, but was subsequently found to have hemagglutinin activity as well as cell fusion activity. More recently, SV has been used as a virus vector ([@bib26]). SV has several unique features that make it suitable for gene transduction because it has a broad range of hosts and expresses transgenes at high levels. Because SV does not have a DNA phase in replicative cycles, the virus genome does not integrate into the host genome. Its usefulness was demonstrated in our previous study, in which SV transduced mouse, hamster, rabbit and marmoset SSCs or SSC-like cells for long-term *in vivo* after xenogeneic transplantation into immunodeficient mice ([@bib50]). This was in contrast to other virus vectors, which showed limited transduction. Although these results clearly showed the superiority of SV over the other virus vectors, the molecular mechanism underlying the efficient transduction of SV remains unclear.

In this study, we hypothesized that the surface properties of SV play a critical role in the transduction efficiency of SSCs. SV has two envelope proteins, HN and F ([@bib21]). HN protein binds to sialic acids on host cells and is required for interaction between SV and host cells. F protein is responsible for the fusion of SV with host cells and is essential for virus entry. These proteins appear to influence transfection efficiency, because several studies have demonstrated that pseudotyping of LVs or simian immunodeficiency viruses (SIVs) with both F and HN improved transduction efficiency to human hepatocytes, respiratory epithelium and several types of cultured cells compared with those pseudotyped with vesicular stomatitis virus G (VSVG) protein ([@bib22], [@bib29], [@bib31]). Based on this hypothesis, we produced several hybrid LVs containing SV-derived envelope proteins and examined their transduction efficiencies as well as their usefulness in gene editing of GS cells.

Results {#sec2}
=======

Failure to Produce Offspring Using SV-Transfected GS Cells {#sec2.1}
----------------------------------------------------------

In our previous study, we showed that SVs transduce GS cells with high efficiency ([@bib50]). Transfected GS cells reinitiated normal spermatogenesis after spermatogonial transplantation. Therefore, we hypothesized that SV would be a useful vehicle for genetic modification of the male germline. Because SV is an RNA virus, we hypothesized that it would induce genetic modification without being transmitted to the next generation. To test this possibility, we transfected GS cells with Azami Green (AG) fluorescent protein-expressing SV ([Figure 1](#fig1){ref-type="fig"}A), and the transfected GS cells were transplanted them into infertile mice. At least 4 weeks after transplantation, the recipients were mated with wild-type females to produce offspring.Figure 1Transduction of GS Cells by Pseudotyped V-LVs(A) Schematic diagrams of an SV and pseudotyped V-LVs by F and/or HN proteins.(B) Histological appearance of a recipient testis transplanted with SV-infected GS cells.(C) Appearance of GS cells 3 days after infection by transduction of pseudotyped LVs without VSVG.(D) Appearance of GS cells 3 days after infection by transduction of pseudotyped LVs with VSVG.(E) Flow cytometric analysis of GS cells 3 days after infection (n = 3). Cells were infected with the same MOI (= 30). V-LVs without PB were used as a control.(F and G) Mean fluorescence intensity (MFI) of VENUS expression (F) and the percentage of cells expressing VENUS (G) were determined. Results of three independent experiments (n = 3; F and G).(H) Failure to improve FV-LV infection efficiency by PB.Scale bars, 50 μm (B--D and H). See also [Figure S1](#mmc1){ref-type="supplementary-material"}. Results are mean ± SEM.

Although more than 12 recipients were mated for more than 6 months, none of the recipient animals produced offspring. GS cell recipients usually produce offspring within 3--4 months ([@bib20]), so these results implied that the SV-infected GS cells had spermatogenic defects. To determine the reason for infertility, we sacrificed the recipient mice and analyzed their testes. Histological analysis revealed that spermatogenesis was severely impaired ([Figure 1](#fig1){ref-type="fig"}B). This was in contrast to the results in our previous study, which showed normal spermatogenesis at 3 months after transplantation ([@bib50]). Therefore, the SV-transfected GS cells gradually lost spermatogenic potential despite colonization and successful differentiation.

Improved Transduction Efficiency of GS Cells by LVs Pseudotyped with F {#sec2.2}
----------------------------------------------------------------------

Although the results detailed in the preceding section revealed the potential toxicity of SV, the mechanism was not clear. There are many structural and functional characteristics that are unique to SV, making it difficult to determine which part of the virus or infection process is responsible for impairing spermatogenic potential. However, because the high infectivity of SVs can be conferred by pseudotyping of LV using F and HN proteins ([@bib22], [@bib29], [@bib31]), we reasoned that a similar pseudotyping strategy might be applicable to SSCs to improve transduction efficiency. We generated three types of LVs pseudotyped with F, HN, or both F and HN (F/HN) proteins ([Figure 1](#fig1){ref-type="fig"}A). These LVs expressed *mNeonGreen* (mNG), a monomeric GFP derived from *Branchiostoma lanceolatum*, under the *Eif1a* promoter. We also used conventional LVs using VSVG as a control. We added polybrene (PB) for V-LV because it enhances the transfection efficiency and is commonly added to SSC infection experiments ([@bib34]). PB was not added to LVs pseudotyped with F or HN proteins. When the GS cells were examined 3 days after transfection, none of the three LVs with SV-derived envelopes showed fluorescence, while HEK293T cells were infected successfully by the three types of LVs ([Figure 1](#fig1){ref-type="fig"}C).

Based on these observations, we carried out another set of experiments by adding VSVG to F or HN proteins. In these experiments, we used VENUS as a fluorescent marker. Contrary to the initial experiments, we were able to detect strong fluorescence in GS cells without PB ([Figure 1](#fig1){ref-type="fig"}D). When compared with each other, VENUS expression level was highest in FV-LV-infected GS cells. To quantify this result, we used flow cytometry ([Figures 1](#fig1){ref-type="fig"}E--1G), which confirmed that the strongest fluorescence was by FV-LVs. The infection efficiency was approximately four times higher than that of V-LVs. HNV-LVs also increased the infection efficiency, albeit at lesser degree. F/HNV-LVs did not improve the infection efficiency and there was no significant difference between HN-LV and F-LV. Adding PB to FV-LV did not increase the infection efficiency ([Figure 1](#fig1){ref-type="fig"}H). These results implied that a combination of F protein and VSVG is important to confer infectivity to GS cells.

To examine the optimal MOI of FV-LVs, we transfected GS cells with FV-LVs expressing *Venus* at an MOI of 1, 5, 15, 30, or 60, and fluorescence levels were analyzed 3 days post-infection by fluorescence microscopy and flow cytometry ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Fluorescence levels were increased in a dose-dependent manner and \>90% of GS cells showed VENUS expression at an MOI of 30--60 ([Figure S1](#mmc1){ref-type="supplementary-material"}C). We next evaluated the effect of FV-LV on cell proliferation. The numbers of GS cells recovered after FV-LV or LV infection were examined at an MOI of 30. Cell recovery after FV-LV infection increased significantly compared with that after V-LV infection ([Figure S1](#mmc1){ref-type="supplementary-material"}D). This difference in cell recovery was likely due to increased apoptosis of V-LV-infected cells, because Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining showed that the number of TUNEL^+^ cells increased by 5-fold after V-LV infection ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

Because PB is potentially toxic ([@bib8]), we checked the toxicity of PB to GS cells. Adding PB decreased cell recovery in a dose-dependent manner 3 days after the treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}F), while the number of TUNEL^+^ cells increased in a reciprocal manner ([Figure S1](#mmc1){ref-type="supplementary-material"}G). An almost 10-fold increase in TUNEL^+^ cells was noted at 10 μg/mL compared with cells cultured without PB. Taken together, these results imply that pseudotyping of LVs with F and VSVG proteins dramatically increases the SSC transduction efficiency with significantly reduced cell toxicity.

Phenotypic Analysis of GS Cells Stably Infected with FV-LVs {#sec2.3}
-----------------------------------------------------------

GS cells transfected with FV-LVs continued to proliferate normally for more than 7 months ([Figure 2](#fig2){ref-type="fig"}A). Because SV-transfected GS cells exhibited a significantly altered phenotype and several downregulated spermatogonia markers, we examined the phenotype of FV-LV-infected cells. We first examined whether FV-LV infection influenced the expression levels of spermatogonia cell surface markers by flow cytometry (KIT, EPCAM, CDH1, ITGA6, ITGB1, CD9, and GFRA1) ([Figure 2](#fig2){ref-type="fig"}B). In contrast to the results of SV infection, which showed downregulation of all examined cell surface markers other than EPCAM ([@bib50]), no significant changes were observed in any tested markers.Figure 2Phenotypic Analysis of GS Cells Infected with FV-LVs(A) *In vitro* expansion of GS cells infected with FV-LV at MOI = 30 and 60.(B) Flow cytometric analysis of surface markers for spermatogonia in FV-LV-infected GS cells. Wild-type GS cells without infection were used as a control. Results of three independent experiments (n = 3).(C) Real-time PCR analysis of spermatogonial markers in FV-LV infected GS cells (n = 3). Results of three independent experiments (n = 3).See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}. Results are mean ± SEM.

We then used real-time PCR to examine the expression of several spermatogonial transcription factors (*Id4*, *Nanos2*, *Nanos3*, *Zbtb16*, *Pou5f1*, *Bcl6b*, *Neurog3*, *Sohlh1*, and *Sohlh2*). Although SV-infected GS cells have been shown to downregulate *Id4*, *Nanos2*, *Zbtb16*, *Pou5f1*, *Bcl6b*, and *Etv5* ([@bib50]), none of these factors was affected by FV-LV infection ([Figure 2](#fig2){ref-type="fig"}C). In summary, FV-LV infection did not disturb cell growth or spermatogonia marker expression.

Transduction Kinetics of Non-integrating FV-LVs {#sec2.4}
-----------------------------------------------

Although FV-LV efficiently infected GS cells without changing the phenotype, LVs integrate into the genome of the infected cells, which potentially alters the expression of neighboring genes. To overcome this problem, we generated integration-deficient FV-LVs (FV-IDLVs) whose integrase had a D64V point mutation leading to the inactivation of integration ([@bib5]). We examined the transduction kinetics of FV-IDLVs in GS cells at an MOI of 120 using fluorescence microscopy and flow cytometry ([Figures 3](#fig3){ref-type="fig"}A and 3B). GS cells with FV-LVs were used as a control (MOI = 30). We used a lower MOI for FV-LVs because preliminary experiments showed weaker fluorescence of FV-IDLVs.Figure 3Transduction Kinetics of Non-integrating FV-LV(A) Appearance of GS cells after FV-LV (top) or FV-IDLV (bottom) infection. Cells were infected at MOI = 30 (FV-LV) or 120 (F-IDLV).(B) Quantification of MFI by flow cytometric analysis. Results of three independent experiments (n = 3).(C) [Experimental Procedures](#sec4){ref-type="sec"}.(D) Flow cytometric analysis of EYFP expression in R26R-*Eyfp* GS cells following infection of *Cre*-expressing F-IDLVs (MOI = 120). Cells were analyzed 5 days after infection. Results of three independent experiments (n = 3).(E) PCR analysis of *Cre*-mediated deletion 3 days after transfection.(F) PCR analysis of *Cre* cDNA after transfection. Cells were passaged three times before analysis at 30 days. Scale bar,= 50 μm (A).See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}. Results are mean ± SEM.

GS cells transfected with FV-IDLV showed mNG fluorescence as early as 1 day after transfection ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Almost all cells exhibited fluorescence in a manner similar to FV-IDLV infection. Expression levels of the FV-IDLV-transfected GS cells peaked at 3 days and gradually declined thereafter. By 10 days after infection, flow cytometry detected few mNG^+^ cells. Even at its peak, the level of mNG fluorescence was less than 2-fold that seen at 1 day after transfection. By contrast, FV-LV-infected GS cells showed mNG expression on the next day after infection and mNG expression gradually increased until 14 days after transfection. Compared with 1 day post-infection, GS cells at this point showed an approximately 30-fold increase in mNG expression.

We examined the utility of FV-IDLVs by infecting GS cells established from R26R-*Efyp* reporter mice, which have a *Pgk-Neo* cassette flanked by *loxP* before *Eyfp* cDNA and express *Eyfp* upon *Cre* transfection ([Figure 3](#fig3){ref-type="fig"}C). Although simple *Cre* overexpression in GS cells induces apoptosis ([@bib18]), AAVs or AVs that transiently express *Cre* can delete the target gene and induce the expression of *Eyfp*. Four days after infection with FV-IDLV-Cre ([Figure S2](#mmc1){ref-type="supplementary-material"}B), EYFP expression was observed in most GS cell from Gt(ROSA)26Sor^tm1(EYFP)Cos^ mice (designated *R2*6R*-Eyfp*); flow cytometry showed that 84% expressed EYFP ([Figure 3](#fig3){ref-type="fig"}D). PCR analysis confirmed the CRE-mediated recombination ([Figure 3](#fig3){ref-type="fig"}E). We also confirmed the lack of *Cre* cDNA 30 days after transfection ([Figure 3](#fig3){ref-type="fig"}F), which suggested that the gradual decline in mNG fluorescence in FV-IDLV-infected GS cells was most likely due to a lack of genome integration. This infection efficiency was comparable with those of AV-Cre and AAV1-Cre ([@bib48]), implying that FV-IDLV is useful for functional analysis of genes by conditional KO in GS cells.

*In Vivo* Transduction into Germ Cells and Sertoli Cells by FV-LVs {#sec2.5}
------------------------------------------------------------------

Because we found that FV-LVs can efficiently transduced GS cells *in vitro*, we examined the feasibility of transducing germ cells *in vivo*. We microinjected FV-LVs expressing VENUS into adult mouse testes at three different doses (1.0 × 10^7^/mL, 1.0 × 10^8^/mL and 1.0 × 10^9^/mL). We used V-LVs as a positive control. The same amount of virus particles was microinjected into the seminiferous tubules or interstitial tissues. When the testes samples were recovered 7 days after microinjection of FV-LVs, VENUS fluorescence was detected regardless of the injection route ([Figure 4](#fig4){ref-type="fig"}A). Although we found VENUS fluorescence in testes with tubular injection of V-LV, no apparent signals were found in testes after interstitial injection.Figure 4*In Vivo* Transduction of Mouse Testes by FV-LVs(A) Macroscopic appearance of testes 7 days after tubular or interstitial injection of *Venus*-expressing FV-LV or V-LVs (1.0 × 10^9^/mL).(B) Immunohistochemistry of FV-LV- and V-LV-infected testes using antibodies against markers for undifferentiated spermatogonia (GFRA1, CDH1), differentiating spermatogonia (KIT), spermatocytes (SYCP3), spermatids (IZUMO1), Sertoli cells (WT1), Leydig cells (HSD3B3), and peritubular myoid cells (SMA).(C and D) Quantification of VENUS expression in each cell type by V-LV (C) and FV-LV (D). Arrowheads indicate cells expressing both VENUS and lineage markers. At least 180 cells in ten tubules were counted. For GFRA1^+^ and CDH1^+^ spermatogonia, 15 cells in ten tubules were counted because there were fewer of them than other cell types. Asterisk indicates statistical significance (p \< 0.05). Results of three independent experiments (n = 3).Scale bars, 1 mm (A), 50 μm (B). See also [Table S1](#mmc1){ref-type="supplementary-material"}. Results are mean ± SEM.

To investigate which cell types of testicular cells were transduced by FV-LVs and V-LVs, we performed immunohistochemistry of testes 7 days post-infection using markers for germ cells (GFRA1: A~single~, A~paired~ spermatogonia and some A~aligned~ spermatogonia; CDH1: undifferentiated spermatogonia; KIT: differentiating spermatogonia; SYCP3: spermatocytes; IZUMO1 for spermatids developing into sperm) and somatic cells (WT1: Sertoli cells: HSD3B3: Leydig cells; SMA: peritubular myoid cells) ([Figure 4](#fig4){ref-type="fig"}B). The number of VENUS^+^ cells expressing each antigen was counted for quantification ([Figures 4](#fig4){ref-type="fig"}C and 4D).

LVs efficiently infected WT1^+^ Sertoli cells in tubular injection, but VENUS expression was barely detectable in germ cells ([Figures 4](#fig4){ref-type="fig"}B and 4C), which confirmed the result of previous studies ([@bib14]). With interstitial injection of V-LVs, germ cells and WT1^+^ Sertoli cells were not infected at all and VENUS signals were detected only in HSD3B3^+^ Leydig cells ([Figures 4](#fig4){ref-type="fig"}B and 4C). By contrast, tubular injection of FV-LVs successfully transduced both germ cells and Sertoli cells. Germ cells were transduced not only in the adluminal compartment but also those in the basal compartment. Similar results were obtained with interstitial injection of FV-LVs ([Figures 4](#fig4){ref-type="fig"}B and 4D). The infection efficiency of germ cells of all germ cells except for IZUMO^+^ cells was \~20%--40% for both infection routes. WT1^+^ Sertoli cells were more efficiently transduced by tubular injection than by interstitial injection (93% versus 66%). Interstitial injection of FV-LVs efficiently transduced HSD3B3^+^ Leydig cells and SMA^+^ peritubular myoid cells, although these cell types were not transduced by tubular injection. Taken together, FV-LVs enabled *in vivo* gene transfer into both undifferentiated spermatogonia and differentiating germ cells regardless of injection route, implying that FV-LVs acquired the ability to penetrate the blood-testis barrier (BTB) and basement membrane of the seminiferous tubules.

Generation of Transgenic Mice Derived from FV-LV Transduced GS Cells {#sec2.6}
--------------------------------------------------------------------

Although these results showed the improved transduction efficiency of FV-LVs, it was possible that F protein influenced spermatogenesis and impaired fertility. To test this possibility, wild-type GS cells were infected with FV-LVs expressing mNG at an MOI of 30 ([Figure 5](#fig5){ref-type="fig"}A). The transfected cells were then cultured for about 2 weeks for *in vitro* expansion before transplantation into busulfan-treated C57BL6/J (B6) × DBA/2 F1 (BDF1) mouse testes. The recipient males were mated with wild-type females to produce offspring. Two months after transplantation, we confirmed extensive colonization of donor GS cells ([Figure 5](#fig5){ref-type="fig"}B). Development of SYCP3^+^ spermatocytes and peanut agglutinin (PNA)^+^ haploid spermatids were confirmed by immunostaining of the recipient testes ([Figure 5](#fig5){ref-type="fig"}C).Figure 5Transgenic Mice Produced by Transfection of GS Cells Using FV-LV Expressing mNG(A) [Experimental Procedures](#sec4){ref-type="sec"}.(B) Macroscopic appearance of a recipient testis transplanted with GS cells infected with mNG-expressing FV-LV.(C) Immunostaining of recipient testis by spermatocyte (SYCP3) and haploid (PNA) markers.(D) Offspring born after spermatogonial transplantation showing donor cell-derived mNG fluorescence under UV light.(E) PCR analysis of mNG transgene in tail DNA.Scale bars, 1 mm (B), 50 μm (C). See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Offspring with normal appearance were obtained at 4 months after spermatogonial transplantation. These mice showed mNG fluorescence under UV light, which confirmed their donor cell origin ([Figure 5](#fig5){ref-type="fig"}D). After genotyping of 16 offspring by PCR to specifically detect transgenes of FV-LVs, seven offspring were found to have transgenes derived from FV-LV infected GS cells ([Figure 5](#fig5){ref-type="fig"}E). These results show that GS cells transduced with FV-LVs retain fertility.

Genome Editing in GS Cells by FV-LVs Expressing CRISPR/Cas9 {#sec2.7}
-----------------------------------------------------------

To study the utility of FV-LVs, we used FV-LVs and GS cells to examine the feasibility of gene editing. We constructed two types of FV-LVs ([Figure 6](#fig6){ref-type="fig"}A). The first vector expressed *spCas9* under the control of *Eif1α* promoter. Another vector expressed guide RNA (gRNA) against *Cldn11* or *Fgf10* exons under the control of human *U6* promoter. We also generated V-LVs containing the same transgenes for control experiments. These viruses were transduced into GS cells, and mutations were analyzed by DNA sequencing 7 and 21 days after infection without drug selection. Although V-LVs scarcely induced mutations, FV-LVs successfully induced mutations in both *Cldn11* and *Fgf10* gene loci ([Figures 6](#fig6){ref-type="fig"}B and 6C). We also quantified genome editing efficiency by Tide analysis ([Figure 6](#fig6){ref-type="fig"}D) ([@bib56]). At day 7 after infection, \<5% of the genomes of V-LV-treated cells were edited, whereas 20%--30% of FV-LV-treated cells were successfully edited. Similarly, at day 21, approximately 70% of the genome of FV-LV-treated cells were mutated, while \~10% of V-LV-treated cells showed evidence of gene editing ([Figure 6](#fig6){ref-type="fig"}C). These results show that FV-LV-mediated gene transfer of CRISPR/Cas9 efficiently induces mutations in GS cells.Figure 6Genome Editing of GS Cells by FV-LVs Using the CRISPR/Cas9 System(A) Schematic diagrams of FV-LVs expressing the CRISPR/Cas9 system. gRNAs against *Cldn11* and *Fgf10* loci in the mouse genome were tested.(B and C) Representative results of sequence analysis in *Cldn11* and *Fgf10* loci at 7 days (B) and 21 days post-infection (C).(D) Quantification of genome editing efficiency in each tested locus by Tide analysis (<https://tide.nki.nl/>). Results of three independent experiments (n = 3).See also [Table S2](#mmc1){ref-type="supplementary-material"}. Results are mean ± SEM.

*In Vivo* Analysis of Gene Functions Involved in Spermatogenesis by Inducible Gene Editing of GS Cells {#sec2.8}
------------------------------------------------------------------------------------------------------

In the final set of experiments, FV-LVs were used for *in vivo* analysis of genes involved in spermatogenesis. We used the Tet-On system to induce CRISPR/Cas9 genome editing ([Figure 7](#fig7){ref-type="fig"}A). The Tet-On system is a drug-inducible gene expression system. rtTA is a transcription factor that can be activated in the presence of dox, and dox-rtTA binds to tetracycline responsive element and induces expression of a gene of interest. We first tested the efficiency of this system *in vitro*. In this experiment, we used gRNAs targeting *Kit* and *Sycp3* exons. *Fgf10* is not expressed in mouse testes and was used as a control (<https://www.ncbi.nlm.nih.gov/gene/14165>). Previous reports on *Kit* mutants showed that *Kit* inactivation abrogates development of differentiating spermatogonia and does not affect SSC self-renewal ([@bib23], [@bib37], [@bib54]). In *Sycp3* KO cells, spermatogonia proliferated normally but meiosis was abrogated ([@bib55]). We transfected these constructs into EGFP-expressing GS cells and produced GS cells with *Kit* (*Kit* GS) or *Sycp3* (*Sycp3* GS) gRNA. One month after transfection, mutation analysis was carried out in GS cells without dox treatment. However, no mutation was found in control, *Kit* and *Sycp3* GS cells ([Figure 7](#fig7){ref-type="fig"}B). To test the efficiency of the Tet-On system, we added dox to GS cells *in vitro* and found that 20%--30% of GS cells were mutated without drug selection ([Figure 7](#fig7){ref-type="fig"}B).Figure 7*In Vivo* Functional Analysis of Spermatogenic Genes Using FV-LVs by Inducible Gene Editing(A) [Experimental Procedures](#sec4){ref-type="sec"} and schematic diagrams of FV-LVs expressing the Tet-On-dependent CRISPR/Cas9 system.(B) Evaluation of mutation levels in dox-treated GS cells by Tide analysis. Results of three independent experiments (n = 3).(C and D) Macroscopic appearance of testes transplanted with GS cells transduced with FV-LV expressing Tet-On CRISPR/Cas9 genes before (C) and after dox treatment (D).(E) Testis weight of transplanted testes after dox treatment (n = 9 for control gRNA; n = 4 for *Sycp3* and *Kit* gRNA). Results of three independent experiments (n = 3).(F and G) Immunostaining of recipient testes before (F) and after (G) dox treatment.(H) Quantification of the number of seminiferous tubules showing EGFP fluorescence and germ cell markers. Results of three independent experiments (n = 3). Asterisks indicates statistical significance (p \< 0.05).Scale bars, 1 mm (C, D), 50 μm (F, G). See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}. Results are mean ± SEM.

To test the usefulness of this system *in vivo*, GS cells were infected by each virus and the transfected cells were transplanted into busulfan-treated mouse testes more than 45 days after infection ([Figure 7](#fig7){ref-type="fig"}A). The recipients received dox via drinking water 2 months after transplantation to induce gene editing *in vivo*. The testes of these mice were analyzed at this point because donor-derived spermatogenesis completes around 2 months after transplantation ([@bib33]). We observed normal colonization of GS cells infected with FV-LV-Tet-CRISPR for each gRNA ([Figure 7](#fig7){ref-type="fig"}C). After administering dox for 35 days, the intensity of donor cell-derived fluorescence was weaker in testes transplanted with *Kit* or *Sycp3* GS cells ([Figure 7](#fig7){ref-type="fig"}D). Consistent with this observation, the testis weight of the *Kit* GS cell sample was significantly decreased ([Figure 7](#fig7){ref-type="fig"}E).

To assess the degree of spermatogenic defect quantitatively, we performed immunostaining of dox-treated testes using antibodies against GFRA1, KIT, and SYCP3 ([Figures 7](#fig7){ref-type="fig"}F and 7G). The testes were also stained with PNA to identify haploid cells. We quantified the number of EGFP^+^ tubules that expressed each marker to confirm donor-derived spermatogenesis ([Figure 7](#fig7){ref-type="fig"}H). The number of tubules expressing GFRA1 did not change. However, the number of tubules with KIT^+^ cells was significantly decreased in testes transplanted with *Kit* GS cells. In recipients with *Sycp3* and *Kit* GS cells, SYCP3^+^ and KIT^+^ tubules were also significantly reduced ([Figure 7](#fig7){ref-type="fig"}G), which was consistent with previous studies. These results suggest that *in vivo* gene editing using FV-LVs with GS cell transplantation is useful for functional analysis of genes associated with spermatogenesis.

Discussion {#sec3}
==========

We initiated this study to overcome the male infertility problem caused by SV infection of GS cells. Although we did not notice abnormalities in initial experiments, the recipients gradually lost spermatogenesis and many empty seminiferous tubules were found in the long-term. Although the exact mechanism underlying this phenomenon is unknown, toxicity of SV has been reported by several groups ([@bib13], [@bib45], [@bib47]). Based on previous reports that showed increased transfection efficiency of LVs pseudotyped with F and HN proteins, we reasoned that these envelope proteins are primarily responsible for the enhanced transduction efficiency of SV and sought to develop a similar LV vector that exhibits increased transduction efficiency without impairing fertility. Although we initially produced LVs with F and HN proteins, these LVs did not infect GS cells. However, because VSVG is often used to increase virus transduction efficiency ([@bib4]), we included VSVG in LV production, which dramatically improved GS cell transfection efficiency.

These newly produced LVs are more useful than conventional SVs for several reasons. First, SVs have immunogenicity and relatively slow clearance of SV RNA ([@bib57]), which might have caused infertility in GS cell recipients. Second, SVs perturb expression of several spermatogonial genes involved in self-renewal and adhesion ([@bib50]). For example, GFRA1, which is a component of GDNF receptor, was significantly downregulated. This might have caused problems *in vivo* because the concentration of GDNF is probably lower *in vivo*. Therefore, although the transfected GS cells retained SSC activity, the decreased GFRA1 expression levels might have interfered with normal SSC self-renewal and contributed to the loss of spermatogenesis. Third, because SVs do not have a DNA phase, gene expression levels and patterns cannot be controlled using conventional DNA-based promoters. In addition to these viral properties, SVs require higher biosafety containment measures, which particularly hampers *in vivo* studies. Moreover, SVs have more restrictions imposed by licensors or vendors ([@bib41]). In this context, pseudotyped LVs are more attractive because they can be readily produced and show significantly improved infectivity.

Pseudotyping of LVs was not as simple as we originally assumed. Because other groups have already demonstrated that LVs or SIVs pseudotyped with both F and HN exhibit improved transduction efficiency in human hepatocytes, respiratory epithelium, and several types of cultured cells ([@bib22], [@bib29], [@bib31]), we expected that pseudotyping with SV envelope proteins alone would be sufficient to improve transfection efficiency. The mechanism of the SV infection process has been well studied. It is thought that SV binds to host cells through interaction between HN proteins and sialic acids of the host cell. Then, SV enters the inside of host cell mediated by the fusion activity of F proteins ([@bib21]). Because sialic acids on GS cells are responsible for SV infection ([@bib27], [@bib50]), expressing both F and HN proteins appeared to be sufficient for GS cell transfection. However, contrary to our expectations, LVs pseudotyped with a combination of F and HN proteins failed to transduce GS cells. The key molecule that led to successful infection was VSVG, because VSVG allowed transduction of GS cells with either F or HN protein. Considering that we were able to infect GS cells with SV in our previous study ([@bib50]), this result implies that additional molecules, with a function similar to VSVG, work cooperatively with F and HN proteins to transduce GS cells during SV infection.

We further showed that pseudotyping with VSVG and F proteins gave the best infection efficiency. This result suggested that HN protein is dispensable for infection. Although we expected HN protein to increase the transduction efficiency, co-transfection of all of these proteins significantly reduced the transduction efficiency. This occurred despite HN protein promoting infection efficiency when it was expressed with VSVG. It is thought that binding of HN protein to the receptor induces a conformational change in the F protein that exposes a hydrophobic region to trigger virion/cell membrane fusion. Given our results, VSVG might have performed the same function as HN to promote initial cell fusion and trigger this conformational change. VSVG was initially used by [@bib4] for lentivirus production and it also acts as a fusion-inducing molecule by itself ([@bib53]). It has been suggested that low-density lipoprotein receptor and its family members serve as cellular receptors for VSVG ([@bib11]). Although we have no direct evidence of interaction between F and VSVG proteins, HN protein might have interfered with this interaction and decreased the fusion efficiency. Because several mutant F proteins that lack fusion activity are available ([@bib38], [@bib39]), future analysis using those mutants will clarify the molecular mechanism by which VSVG and F proteins cooperate for efficient fusion.

In addition to the increased transduction efficiency, pseudotyping with the F protein made it possible for F-LVs to penetrate the BTB as well as the basement membrane of the seminiferous tubules. Although LVs have been used to transduce SSCs *in vitro* and have the ability to disrupt the tight junctions in the blood-brain barrier (BBB) ([@bib36], [@bib43]), it has not been possible to transduce spermatogenic cells *in vivo*. Although the mechanism underlying these phenomena is currently unknown, increased infectivity must play a role because neither SVs nor LVs alone could infect germ cells *in vivo*. To penetrate the basement membrane, it is possible that viruses that have high transduction efficiency infect spermatogonia and early spermatocytes, because exogenous antibodies can reach these cell populations after intravenous administration ([@bib54]). By contrast, the penetration of the BTB is currently inexplicable. We recently showed that AAVs can similarly transduce spermatogenic cells *in vivo* by penetrating the BTB ([@bib49]). Because AAVs are thought to pass through the BBB by transcytosis ([@bib10]), it seems reasonable to speculate that LVs penetrated the BTB by transcytosis in the same manner. Indeed, transcytosis of LVs has been reported ([@bib12]).

Unlike SVs, FV-LV did not alter spermatogonial marker gene expression, and normal offspring were produced by natural mating of GS cell recipients. Therefore, FL-LV can overcome the most critical problem associated with SV infection. We further demonstrated the utility of FV-LVs by making FV-IDLVs with inducible gene editing. Although the expression levels of transgenes by FV-IDLVs was lower than those achieved by FV-LVs, they did successfully transfect GS cells and induce *Cre-loxP* recombination in *R2*6R*-Eyfp* GS cells in a manner similar to AVs and AAVs ([@bib44], [@bib48]). By contrast, gene editing and subsequent transplantation of GS cells have created a new opportunity to analyze spermatogenesis in a functional manner. Genome editing in GS cells is a laborious process because of the relatively low infection efficiency and slow proliferation of GS cells. However, conventional methods of gene transfer, such as electroporation and subsequent drug selection have demonstrated the feasibility of gene editing in these cells ([@bib6], [@bib40], [@bib52]). Because we achieved genome editing of more than 20% of GS cells by FV-LVs without drug selection, we could directly analyze the function of the target gene in less time. Currently, a range of applications of CRISPR/Cas9 is available, including epigenome editing, chromatin imaging plus manipulation and base editing ([@bib1]). Combining FV-LV-mediated gene transfer with these tools will greatly facilitate functional analysis of SSC self-renewal and spermatogenic differentiation.

Our study showed that pseudotyping of LVs with F proteins not only overcomes the problems associated with SVs but also improves the transduction efficiency and changes the transduction patterns of original LVs. It will be interesting to examine whether these newly generated LVs can transduce SSCs from other animal species that are resistant to conventional LV transfection. The ability to penetrate the BTB and the basement membrane of the seminiferous tubules will also improve the efficiency of genetic modification of male germ cells *in vivo*. Theoretically, almost all membrane proteins can be used for LV pseudotyping. They are not limited to virus envelope proteins and species of organisms, and include membrane-associated antibodies and artificially engineered membrane proteins. Therefore, it is likely that even better molecules may become available for improving the transduction efficiency. Thus, our study provides a basis for developing optimized protocols for SSC transduction, and future studies will overcome the problems associated with genetic manipulation of the male germline.

Experimental Procedures {#sec4}
=======================

Lentivirus Construction and Infection {#sec4.1}
-------------------------------------

In experiments to determine the transfection properties in GS cells, we used *CSII-Eif1a-IRES2-Venus* or *CSII-Eif1a-mNG*. mNG cDNA was purchased from Allele Biotechnology (San Diego, CA) and cloned into a *CSII-Eif1a* vector. For production of LV with VSVG (V-LV), PB (Sigma) was added at a final concentration of 10 μg/mL. LV particles were prepared as described previously ([@bib30]). To prepare 1.0 × 10^9^/mL of LVs, virus supernatants were concentrated by ultrafiltration (Amicon Ultra-4 4ML - 100 kDa cutoff, UFC810096, Millipore, Darmstadt, Germany) using PBS. To produce pseudotyped LVs, *pCAG-F* and/or *pCAG-HN*, *pCAG-HIVgp*, and *pCMV-VSV-G-RSV-Rev* were co-transfected with pCSII vector into HEK293T cells. *F* and *HN* cDNAs were derived from the Z strain of an SV (a gift from Dr. T. Irie, Hiroshima University, Hiroshima, Japan). To prepare FV-IDLV, we used *psPAX2-D6*4V ([@bib5]), *pMD2-G*, *pCAG-F*, and *pCSII-Eif1a-Cre*. For production of LVs expressing CRISPR/Cas9, we used *lentiCas9-Blast* (no. 52962; Addgene, Watertown, MA) and *lentiGuide-Puro* (no. 52963, Addgene). To construct inducible LVs expressing Tet-On CRISPR/Cas9, *spCas9* cDNA was amplified by PCR using *pX330-U6-Chimeric-BB-CBh-hSpCas9* ([@bib7]) as a template, and cloned into *pTetO-FUW* ([@bib2]). We also cloned *rtTA* cDNA (a gift from Dr. K. Yagita, Kyoto Prefectural University of Medicine, Kyoto, Japan) into *pCSII-Eif1a* vector. The following gRNA sequences were used in this study; *Fgf1*0 gRNA (5′-TGTTTGGATCGTCATGGGG-3′), *Cldn1*1 gRNA (5′-ATGGGCCACGAGCCTGGAG-3′), *Sycp3* gRNA (5′-TTTTAGGCTGATCAACCAA-3′), and *Kit* gRNA (5′-TCAGCCATCTGCAAGTCCA-3′). The titers of all types of viruses used in this study were measured using a Lenti-X p24 Rapid Titer Kit (Clontech, Mountain View, CA) according to the manufacturer\'s instructions. All types of LVs were infected at the indicated MOI, which ranged from 0 to 60.

Statistical Analyses {#sec4.2}
--------------------

Results are presented as the means ± SEM. Data were analyzed using Student\'s *t*-test. Multiple comparison analyses were performed using ANOVA followed by Tukey\'s HSD test.
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